This prospective study describes the feasibility and toxicity of (192)Iridium high-dose-rate (HDR) brachytherapy as an alternative strategy for the treatment of canine intranasal tumours. Fifteen dogs with malignant intranasal tumours were treated twice weekly using a hypofractionated protocol with eight fractions, 5 Gy per fraction, resulting in a total dose of 40 Gy. Acute and chronic adverse side-effects appeared to be rare. Only 7% of the acute side-effects and 5% of the chronic were classified as severe (grade 3). Eight dogs showed clinical complete remission, and five dogs had partial remission, with a resolution of tumour-related symptoms. Magnetic resonance imaging showed a reduced tumour mass in 12 cases. Median survival time was 17 months (range 4-48 months), with four dogs (three without disease) still alive. Median time to recurrence of these dogs was 14 months. In nine dogs, progression or recurrence of the tumour was the cause of death. This study suggests that HDR brachytherapy is feasible and well tolerated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1476-5829.2006.00109.x | DOI Listing |
Hum Vaccin Immunother
December 2025
TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
The dissemination of tumor cells with ensuing metastasis is responsible for most cancer-related deaths. Cancer vaccines may, by inducing tumor-specific effector T cells, offer a strategy to eliminate metastasizing tumor cells. However, several obstacles remain in the development of effective cancer vaccines, including the identification of adjuvants that enhance the evolvement and efficacy of tumor-specific T cells.
View Article and Find Full Text PDFJ Surg Case Rep
January 2025
Department of Otolaryngology Head and Neck Surgery, King Fahad Specialist Hospital, Dammam 43221, Saudi Arabia.
Giant rhinoliths are uncommon, mineralized concretions that usually develop around an intranasal foreign substance in the nasal canal. These lesions frequently cause respiratory problems, foul-smelling discharge, and nasal blockage. Clinical examination, endoscopy, and radiological imaging are used to make the diagnosis, and surgical removal is the only effective therapy.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
IRCCS Humanitas Research Hospital, Rozzano, Italy
Background: ACKR2 is an atypical chemokine receptor that plays a significant role in regulating inflammation by binding to inflammatory CC chemokines and facilitating their degradation. Previous findings suggest that the genetic absence of ACKR2 leads to heightened tumor growth in inflammation-driven models. Conversely, mice lacking ACKR2 exhibit protection against lung metastasis in melanoma and breast cancer models.
View Article and Find Full Text PDFJ Pain Res
January 2025
Programa de Pós-Graduação em Medicina (Cirurgia Geral), Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Introduction: Diabetes mellitus (DM) has become a public health problem, which is associated with high morbidity and mortality, due to the chronic complications, such as diabetic neuropathy. Current recommendations for the treatment of neuropathic pain achieve a reduction of 30% in only 30% of cases. Therefore, it is necessary to identify new therapeutic approaches to improve the quality of life of diabetic patients.
View Article and Find Full Text PDFBraz J Vet Med
January 2025
Veterinarian, DSc. Departamento de medicina e cirurgia veterinária, Instituto de Veterinária, Universidade Federal Rural do Rio de Janeiro. Seropédica, RJ, Brazil.
Epistaxis is defined as bleeding from the nasal cavity and can be related to systemic causes leading to coagulation disorders, most commonly hemoparasitosis, or to localized changes in the nasal cavity itself (e.g., intranasal neoplasms).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!